<DOC>
	<DOC>NCT01653158</DOC>
	<brief_summary>This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.</brief_summary>
	<brief_title>CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Age greater than 18 years Documented advancedstage nonhematologic malignancy for whom docetaxel monotherapy is a reasonable treatment option Eastern Cooperative Oncology Group [ECOG] performance status 01 Significant active cardiac disease Chemotherapy, biological or investigational agents within 4 weeks prior to dosing Inadequate bone marrow, renal, cardiac or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>non-hematologic cancer</keyword>
	<keyword>advanced solid tumors</keyword>
	<keyword>prostrate cancer</keyword>
</DOC>